Mechanisms of Glucose Counterregulation in Pancreatic Islet Transplantation
Primary Purpose
Type 1 Diabetes Mellitus
Status
Completed
Phase
Phase 4
Locations
Germany
Study Type
Interventional
Intervention
Hypoglycemic and euglycemic glucose clamp
Sponsored by
About this trial
This is an interventional basic science trial for Type 1 Diabetes Mellitus focused on measuring Type 1 diabetes mellitus, hypoglycemia counterregulation,, pancreatic islet transplantation
Eligibility Criteria
T1DM/ITX+
Inclusion Criteria:
- Type 1 Diabetes
- Pancreatic islet transplantation
Exclusion Criteria:
- Type 2 Diabetes
Sites / Locations
- Justus Liebig University
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Placebo Comparator
Active Comparator
Arm Label
Islet transplant recipients
Type 1 diabetic subjects
Non-diabetic subjects
Arm Description
Hypoglycemic and euglycemic glucose clamp
Hypoglycemic and euglycemic glucose clamp.
Hypoglycemic and euglycemic glucose clamp
Outcomes
Primary Outcome Measures
Whole body glucose counterregulation
Whole body glucose counterregulation is the difference in glucose infusion rates required to maintain the glycemic goal between the hypoglycemic and euglycemic clamp. Clamps were performed at two time points at least two weeks apart. Participants will be followed for the duration of 6-8 weeks to perform the hypoglycemic and euglycemic clamp tests.
Secondary Outcome Measures
Systemic glucose release
Systemic glucose release is the amount of glucose released primarily from the liver into the blood compartment during a given time. The unit of measure is μmol/kg/min.
Participants will be followed for the duration of 6-8 weeks to perform the hypoglycemic and euglycemic clamp tests that will yield this parameter.
Skeletal muscle glucose disposal
Participants will be followed for the duration of 6-8 weeks to perform the euglycemic and hypoglycemic clamp tests. The unit of measure of this parameters is μmol/kg/min.
Gluconeogenesis from lactate
This parameter is determined by labelled lactate infused into the proband. The rate of the de novo synthesis of glucose (gluconeogenesis) is determined by the degree of incorporation of the lactate label into glucose molecules. The unit of measure of this parameter is μmol/kg/min.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01668485
Brief Title
Mechanisms of Glucose Counterregulation in Pancreatic Islet Transplantation
Official Title
Metabolic Studies in Type 1 Diabetic Patients After Allogenic Intraportal Islet Transplantation.
Study Type
Interventional
2. Study Status
Record Verification Date
August 2012
Overall Recruitment Status
Completed
Study Start Date
November 2001 (undefined)
Primary Completion Date
November 2010 (Actual)
Study Completion Date
November 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Giessen
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Pancreatic islet transplantation improves glucose counterregulation and stabilizes glycemic control in patients with type 1 diabetes mellitus prone to severe hypoglycemia even if insulin independence is not achieved. However, the extent and underlying metabolic pathways of this improvement are unknown. Investigators therefore compare systemic glucose turnover including lactate gluconeogenesis and muscle glucose utilization, between insulin-requiring islet transplant recipients, matched type 1 diabetic subjects who did not receive islet transplantation, and matched healthy non-diabetic subjects.
Detailed Description
Subjects (n=12 each group) undergo a hypoglycemic and a euglycemic hyperinsulinemic clamp in a randomized fashion. Systemic and skeletal muscle glucose and lactate kinetics are assessed using a combination of isotopic and forearm balance techniques.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 1 Diabetes Mellitus
Keywords
Type 1 diabetes mellitus, hypoglycemia counterregulation,, pancreatic islet transplantation
7. Study Design
Primary Purpose
Basic Science
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
36 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Islet transplant recipients
Arm Type
Experimental
Arm Description
Hypoglycemic and euglycemic glucose clamp
Arm Title
Type 1 diabetic subjects
Arm Type
Placebo Comparator
Arm Description
Hypoglycemic and euglycemic glucose clamp.
Arm Title
Non-diabetic subjects
Arm Type
Active Comparator
Arm Description
Hypoglycemic and euglycemic glucose clamp
Intervention Type
Procedure
Intervention Name(s)
Hypoglycemic and euglycemic glucose clamp
Intervention Description
Each study participant will be subjected to a continuous infusion of insulin at a rate of 0.8 mU·kg-1·min-1 to induce hypoglycemia (blood glucose 2.8-3 mmol/l) for 30 minutes. At least two weeks later an identical insulin infusion will be administered and euglycemia (blood glucose 5 mmol/l) will be targeted. The order of these interventions will be subject to randomization.
Primary Outcome Measure Information:
Title
Whole body glucose counterregulation
Description
Whole body glucose counterregulation is the difference in glucose infusion rates required to maintain the glycemic goal between the hypoglycemic and euglycemic clamp. Clamps were performed at two time points at least two weeks apart. Participants will be followed for the duration of 6-8 weeks to perform the hypoglycemic and euglycemic clamp tests.
Time Frame
6-8 weeks
Secondary Outcome Measure Information:
Title
Systemic glucose release
Description
Systemic glucose release is the amount of glucose released primarily from the liver into the blood compartment during a given time. The unit of measure is μmol/kg/min.
Participants will be followed for the duration of 6-8 weeks to perform the hypoglycemic and euglycemic clamp tests that will yield this parameter.
Time Frame
6-8 weeks
Title
Skeletal muscle glucose disposal
Description
Participants will be followed for the duration of 6-8 weeks to perform the euglycemic and hypoglycemic clamp tests. The unit of measure of this parameters is μmol/kg/min.
Time Frame
6-8 weeks
Title
Gluconeogenesis from lactate
Description
This parameter is determined by labelled lactate infused into the proband. The rate of the de novo synthesis of glucose (gluconeogenesis) is determined by the degree of incorporation of the lactate label into glucose molecules. The unit of measure of this parameter is μmol/kg/min.
Time Frame
6-8 weeks
10. Eligibility
Sex
All
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
T1DM/ITX+
Inclusion Criteria:
Type 1 Diabetes
Pancreatic islet transplantation
Exclusion Criteria:
Type 2 Diabetes
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas Linn, MD
Organizational Affiliation
Justus Liebig University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Justus Liebig University
City
Giessen
State/Province
Hessia
ZIP/Postal Code
35392
Country
Germany
12. IPD Sharing Statement
Citations:
PubMed Identifier
24305963
Citation
Ang M, Meyer C, Brendel MD, Bretzel RG, Linn T. Magnitude and mechanisms of glucose counterregulation following islet transplantation in patients with type 1 diabetes suffering from severe hypoglycaemic episodes. Diabetologia. 2014 Mar;57(3):623-32. doi: 10.1007/s00125-013-3120-9. Epub 2013 Dec 5.
Results Reference
derived
Learn more about this trial
Mechanisms of Glucose Counterregulation in Pancreatic Islet Transplantation
We'll reach out to this number within 24 hrs